MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy

• Published in: American journal of obstetrics and gynecology 2008, Vol.198 (1), p.99.e1-99.e7
• Main Authors: Napoletano, Chiara, PhD, Bellati, Filippo, MD, Tarquini, Elisabetta, MD, Tomao, Federica, MD, Taurino, Federica, PhD, Spagnoli, Giulio, MD, Rughetti, Aurelia, PhD, Muzii, Ludovico, MD, Nuti, Marianna, PhD, Benedetti Panici, Pierluigi, MD
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antigens, Neoplasm - genetics; Antigens, Neoplasm - metabolism; Biological and medical sciences; Biomarkers, Tumor - analysis; Biopsy, Needle; cancer testis tumor-associated antigens; cervical cancer; Chemotherapy, Adjuvant; Cohort Studies; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Hysterectomy - methods; Immunohistochemistry; MAGE-A; Medical sciences; Membrane Proteins - genetics; Membrane Proteins - metabolism; Middle Aged; neoadjuvant chemotherapy; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; NY-ESO-1; Obstetrics and Gynecology; Probability; Prognosis; Sensitivity and Specificity; Survival Analysis; Tissue Culture Techniques; Treatment Outcome; Tumors; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - surgery
• ISSN: 0002-9378; 1097-6868
• DOI: 10.1016/j.ajog.2007.05.019

Objective The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. Study Design One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. Results MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases ( P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading ( P = .039). Conclusion Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.